What "conservative dosing" actually means

Every injector in Maryland will tell you they dose conservatively. The phrase has been repeated until it means almost nothing, so let me rebuild it from the published record. Start with what a dose even is. The FDA label for Botox specifies the studied glabellar treatment precisely: four units at each of five injection points between and above the brows,
twenty units in all. That number is not a suggestion pulled from experience. It is the dose that carried the pivotal trials, in which 80 percent of treated patients were rated improved at maximum frown on day 30, against 3 percent of placebo. Patients agreed with the investigators: 89 percent rated themselves improved, versus 7 percent on placebo.

Notice what else those trials recorded. By day 7, 74 percent of patients had already responded. Effect in the studies was measured through day 120, and the label states the practical translation: roughly three to four months of duration. So the honest timeline reads like this. First movement change inside a week. Results building over the following days. Peak measured at one month. A slow return of motion over three to four months. Any injector promising you a final verdict in the mirror on day 2 is ahead of their own product.

d

That timeline is why the two-week recheck exists, and it is in the literature rather than folklore. The consensus recommendations published by Carruthers and colleagues advise reassessing facial treatments one to two weeks after injection, when the effect is established enough to judge and early enough to refine. At Aether the recheck is free and written into policy: anything uneven or under-dosed at two weeks gets corrected then, no charge. Toxin is easy to add and impossible to subtract, so the sequence is exam, a measured first dose, then adjustment against evidence. If 24 units might do it, I would rather place 20 and add 4 where the movement says so. The reverse mistake has no remedy except waiting out the duration curve.

The exam deserves its own sentence, because the label dose is a starting map and faces are not standardized. Muscle mass differs, and a heavier frontalis or forty years of trained brow movement changes the plan. I ask patients to raise, frown, squint, and hold still, because muscle at rest and muscle in motion tell different stories. Dosing from a price sheet instead of a moving face is how foreheads end up frozen.

And about price sheets: unit prices are only comparable within the same product. Botox and Dysport units are defined by different assays, and the FDA labels of both state outright that units are not interchangeable between products. Clinical studies comparing them have most often used ratios around two and a half Dysport units per Botox unit. We charge $15 per unit for Botox and Xeomin and $6 for Dysport, and quoting those side by side without the conversion caveat would be comparing meters to feet. A practice advertising a startlingly low unit price is recovering the margin somewhere, and volume is the usual place. Volume pressure and careful dosing pull in opposite directions.

No provider can promise a result in advance, and the trial data above is exactly why: even at the label dose, one patient in five was not rated improved at day 30. What a careful injector can promise is a plan built from your anatomy, a measured first pass, and a scheduled two-week look at the outcome with a willingness to adjust. That is conservative dosing. Everything else is a slogan.

Sources

BOTOX Cosmetic Prescribing Information, FDA, rev. 2024 (dosing §2.2, trial data §14.1) · Carruthers et al., Plastic and Reconstructive Surgery, 2002 (pivotal glabellar trial) · Carruthers et al., consensus recommendations, Plast Reconstr Surg 2004 and 2016 (1-2 week reassessment) · Yun et al., 2015 (2.5:1 Dysport conversion in comparative study)